Marlous Kooijman

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

Peter J.K. van Meer, Marlous Kooijman, Vera Brinks et al. · mAbs · 2013 · 128 citations · Full text

Veterinary Vaccine, Immunohematology, Immunodeficiencies +18

The ability of animal studies to detect serious post marketing adverse events is limited

Peter J.K. van Meer, Marlous Kooijman, Christine C. Gispen‐de Wied et al. · Regulatory Toxicology and Pharmacology · 2012 · 60 citations · Full text

Animal Testing, Advertising, Preventive Medicine +8

How institutional logics hamper innovation: The case of animal testing

Marlous Kooijman, Marko P. Hekkert, Peter J.K. van Meer et al. · Technological Forecasting and Social Change · 2017 · 28 citations · Full text

Institutional Innovation, Management, Business +5

Why Animal Studies are Still Being Used in Drug Development

Marlous Kooijman · Alternatives to Laboratory Animals · 2013 · 13 citations

Pharmaceutical Innovation, Laboratory Animal Study, Animal Study +18